Characteristics of 9194 Patients With Left Ventricular Hypertrophy

Hypertension - Tập 32 Số 6 - Trang 989-997 - 1998
Björn Dahlöf1, Richard B. Devereux1, Stevo Julius1, Sverre E. Kjeldsen1, Gareth Beevers1, Ulf dé Fairé1, Frej Fyhrquist1, Thomas Hedner1, Hans Ibsen1, Krister Kristianson1, Ole Lederballe‐Pedersen1, Lars Lindholm1, Markku S. Nieminen1, Per Omvik1, Suzanne Oparil1, Hans Wedel1
1From Sahlgrenska University Hospital/Östra, Göteborg, Sweden (B.D.); New York Hospital–Cornell Medical Center, New York, NY (R.B.D.); University of Michigan Medical Center, Ann Arbor, Michigan (S.J.); Ullevaal University Hospital, Oslo, Norway (S.E.K.); City Hospital, Birmingham, UK (G.B.); Karolinska University Hospital, Stockholm, Sweden (U. de F.); Helsinki University Central Hospital, Helsinki, Finland (F.F., M.S.N.); Sahlgrenska University Hospital, Göteborg, Sweden (T.H.); Glostrup...

Tóm tắt

Abstract —Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the β-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years, and ECG-documented left ventricular hypertrophy (LVH) were included. Altogether, 9223 patients in Scandinavia, the United Kingdom, and the United States were randomized from June 1995 through April 1997, and 9194 remain after exclusion of a study center at which irregularities were discovered. This population of hypertensives (mean systolic/diastolic blood pressure, 174.4/97.8 mm Hg) with LVH comprises women (54.1%) and men, mostly retired from active work (mean age, 66.9 years), with a high prevalence of overweight (mean body mass index, 28.0 kg/m 2 ), diabetes mellitus (12.3%), lipid disorders (18.0%), and symptoms or signs of coronary heart disease (15.1%). There were fewer current smokers (<17%) than in the general population, and ≈7% were nonwhite. Almost 30% of participants had been untreated for at least 6 months when screened for the study. Only 1557 persons who entered the placebo run-in period of 14 days were excluded, predominantly because of sitting blood pressures above or below the predetermined range of 160-200/95-115 mm Hg and ECG-LVH criteria not met. By application of simple 12-lead ECG criteria for LVH (Cornell voltage QRS duration product formula plus Sokolow-Lyon voltage read by a core laboratory), hypertensive patients with LVH with an average 5-year coronary heart disease risk of 22.3% according to the Framingham score were identified. This population is now being treated (goal, <140/90 mm Hg) in adherence with the protocol for at least 4 years after final enrollment (ie, through April 2001) and until at least 1040 patients suffer myocardial infarction, stroke, or cardiovascular death.

Từ khóa


Tài liệu tham khảo

Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;46:205–225.

10.1016/S0002-9149(99)80413-5

10.1001/archinte.1995.00430040081010

10.1056/NEJM199005313222203

10.7326/0003-4819-114-5-345

10.1001/jama.1995.03520440046035

Camargo MJF von Lutterotti N Pecker MS James GD Timmermans PBMWM Laragh JH. DuP753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet. Am J Hypertens. 1991;4(pt 2):341S–345S.

von Lutterotti N Camargo MJF Mueller FB Timmermans PBMWM Laragh JH. Angiotensin II receptor antagonist markedly reduces mortality in salt-loaded Dahl S rats. Am J Hypertens. 1991;4 (pt 2):346S–349S.

10.1161/circ.89.5.8181153

10.1016/0895-7061(95)00338-X

10.1016/S0140-6736(97)01187-2

10.1016/S0895-7061(97)00054-X

10.1016/0735-1097(92)90376-X

10.1161/hyp.25.2.242

10.1016/0735-1097(94)00371-V

10.1016/0735-1097(95)00269-5

10.1016/0002-8703(49)90562-1

10.1161/circ.75.3.2949887

10.1161/circ.83.1.1984895

10.1001/jama.1991.03460240051027

10.1016/0140-6736(91)92589-T

10.1136/bmj.306.6883.983

10.1001/archinte.1997.00440420033005

10.1097/00004872-199309000-00004

10.3109/08037059409102281

10.1016/S0140-6736(98)04311-6

10.3109/08037059609062111

10.1097/00004872-199715030-00005

Thông tin
Thông tin xuất bản

Hypertension

Tập 32 Số 6

989-997

Thông tin tác giả